Reuters logo
Biogen, AbbVie multiple sclerosis drug wins EU green light
April 29, 2016 / 11:31 AM / 2 years ago

Biogen, AbbVie multiple sclerosis drug wins EU green light

LONDON (Reuters) - A once-monthly injection for multiple sclerosis from Biogen and AbbVie has been recommended for approval by European regulators, paving the way for its launch in the coming months.

A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid

The European Medicines Agency said on Friday its experts had endorsed Zinbryta, or daclizumab, for the treatment of relapsing forms of multiple sclerosis (MS), adding a new option to a range of modern MS therapies.

The positive opinion will now be referred to the European Commission, which normally grants marketing authorizations for medicines recommended by the agency within a couple of months.

The self-administered, under-the-skin injection is also currently being reviewed by regulators in the United States, Switzerland, Canada and Australia.

Reporting by Ben Hirschler; Editing by Mark Potter

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below